The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection

  • Dimitra Ioanna Lampropoulou Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece https://orcid.org/0000-0003-3696-8550
  • Vanessa Meletia Bala Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece https://orcid.org/0000-0003-1423-2489
  • Eleni Zerva Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece https://orcid.org/0000-0002-7974-0321
  • Evangelia Pliakou Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece https://orcid.org/0000-0003-0775-1715
  • Dimitrios Filippou Department of Anatomy and Surgical Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece https://orcid.org/0000-0001-5410-3046
  • Maria Gazouli Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece https://orcid.org/0000-0002-3295-6811
  • Gerasimos Aravantinos Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece https://orcid.org/0000-0002-2106-1713
Keywords: SARS-CoV-2, PARP-1 inhibitors, VEGF, bevacizumab, olaparib

Abstract

Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.

Methodology: We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection.

Results: poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients.

Conclusions: The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis.

Downloads

Download data is not yet available.

Author Biographies

Dimitra Ioanna Lampropoulou, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

1. Clinical Trials Unit Leader, PharmD, MSc, PhD, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

2. Member of the Committee for the Medical Information and Advertising Control at National Organization for Medicines (EOF)

3. Post Doctoral Researcher in Cancer Pharmacogenomics at Medical School - National & Kapodistrian University of Athens, Greece.

Vanessa Meletia Bala, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

Medical Oncology Resident, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

Eleni Zerva, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

Research Pharmacist, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

Evangelia Pliakou, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

MD in the Hellenic Navy, MSc, Medical Oncology Resident, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

Dimitrios Filippou, Department of Anatomy and Surgical Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece

1. Presidentof the Greek National Medicines Agency (EOF)

2. Assistant Professor, Department of Anatomy and Surgical Anatomy, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.

Maria Gazouli, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
1. Professor, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.

2. Member of the European Proteomics Association (EuPA)

3. Visiting Professor at University of Erlangen-Nuremberg and Università degli Studi di Sassari

Gerasimos Aravantinos, Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

1. Medical Oncologist, PhD

2. Scientific Director and Head of Second Department of Medical Oncology, General Oncology Hospital of Kifissia “Agioi Anargiroi”, Athens, Nea Kifissia, Greece

Published
2022-01-31
How to Cite
1.
Lampropoulou DI, Bala VM, Zerva E, Pliakou E, Filippou D, Gazouli M, Aravantinos G (2022) The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection. J Infect Dev Ctries 16:101-111. doi: 10.3855/jidc.15386
Section
Coronavirus Pandemic